Correction: Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial (The Lancet Gastroenterology & Hepatology (2017) 2(8) (565–75) (S2468125317301565)(10.1016/S2468-1253(17)30156-5));Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial

The Lancet Gastroenterology and Hepatology

Volumn 2, Issue 8, 2017, Pages 565-575

  Meyer, Tim ^a,b   Fox, Richard ^c   Ma, Yuk Ting ^d   Ross, Paul J ^e,f   James, Martin W ^e,g   Sturgess, Richard ^h   Stubbs, Clive ^c   Stocken, Deborah D ⁱ   Wall, Lucy ^j   Watkinson, Anthony ^k   Hacking, Nigel ^l   Evans, T R Jeffry ^m   Collins, Peter ⁿ   Hubner, Richard A ^o   Cunningham, David ^p   Primrose, John Neil ^l   Johnson, Philip J ^q   Palmer, Daniel H ^q,r  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^e GUY S HOSPITAL   (United Kingdom)

^f KING S COLLEGE HOSPITAL   (United Kingdom)

^g NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^h UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

ⁱ NEWCASTLE UNIVERSITY   (United Kingdom)

^j WESTERN GENERAL HOSPITAL   (United Kingdom)

^k ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^l UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^m UNIVERSITY OF GLASGOW   (United Kingdom)

ⁿ BRISTOL ROYAL INFIRMARY   (United Kingdom)

^o CHRISTIE HOSPITAL   (United Kingdom)

^p INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^q UNIVERSITY OF LIVERPOOL   (United Kingdom)

^r CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; DOXORUBICIN; PLACEBO; SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PROTEIN KINASE INHIBITOR;

ABDOMINAL PAIN; ADULT; AGED; ALGORITHM; ALOPECIA; ANOREXIA; ARTICLE; BLEEDING; CANCER GROWTH; CHEMOEMBOLIZATION; CHILD PUGH SCORE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELUTING BEAD; DRUG SAFETY; DRY SKIN; FATIGUE; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; LIVER CELL CARCINOMA; LOSS OF APPETITE; MALE; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; NUTRITION; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RASH; SOCIAL INTERACTION; STOMATITIS; SUSTAINED RELEASE PREPARATION; TREATMENT OUTCOME; VOMITING; ANALOGS AND DERIVATIVES; ARTIFICIAL EMBOLIZATION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; INTENTION TO TREAT ANALYSIS; KAPLAN MEIER METHOD; LIVER TUMOR; MULTIMODALITY CANCER THERAPY;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; EMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; TREATMENT OUTCOME;

EID: 85021741779     PISSN: 24681253     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2468-1253(17)30226-1     Document Type: Erratum

References (29)

1. Ferlay, J, Soerjomataram, I, Dikshit, R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136 (2015), E359–E386.
2. European Association For The Study Of The Liver, European Organisation For Research and Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56 (2012), 908–943.
3. Llovet, JM, Real, MI, Montana, X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359 (2002), 1734–1739.
4. Llovet, JM, Bruix, J, Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37 (2003), 429–442.
5. Lo, CM, Ngan, H, Tso, WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35 (2002), 1164–1171.
6. Marelli, L, Stigliano, R, Triantos, C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30 (2007), 6–25.
7. Meyer, T, Kirkwood, A, Roughton, M, et al. A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. Br J Cancer 108 (2013), 1252–1259.
8. Brown, KT, Do, RK, Gonen, M, et al. Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone. J Clin Oncol 34 (2016), 2046–2053.
9. Oliveri, RS, Wetterslev, J, Gluud, C, Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev, 3, 2011 CD004787.
10. Lammer, J, Malagari, K, Vogl, T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33 (2010), 41–52.
11. Golfieri, R, Giampalma, E, Renzulli, M, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer 111 (2014), 255–264.
12. Vogl, TJ, Lammer, J, Lencioni, R, et al. Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. AJR Am J Roentgenol 197 (2011), W562–W570.
13. Llovet, JM, Ricci, S, Mazzaferro, V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008), 378–390.
14. Cheng, AL, Kang, YK, Chen, Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10 (2009), 25–34.
15. Bruix, J, Takayama, T, Mazzaferro, V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 16 (2015), 1344–1354.
16. Bruix, J, Sherman, M, for the Practice Guidelines Committee. Management of hepatocellular carcinoma. Hepatology 42 (2005), 1208–1236.
17. Eisenhauer, EA, Therasse, P, Bogaerts, J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009), 228–247.
18. Lencioni, R, Llovet, JM, Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30 (2010), 52–60.
19. Freidlin, B, Korn, EL, Gray, R, A general inefficacy interim monitoring rule for randomized clinical trials. Clin Trials 7 (2010), 197–208.
20. Billingham, LJ, Abrams, KR, Simultaneous analysis of quality of life and survival data. Stat Methods Med Res 11 (2002), 25–48.
21. Dufour, JF, Hoppe, H, Heim, MH, et al. Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. Oncologist 15 (2010), 1198–1204.
22. Pawlik, TM, Reyes, DK, Cosgrove, D, Kamel, IR, Bhagat, N, Geschwind, JF, Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol 29 (2011), 3960–3967.
23. Chung, YH, Han, G, Yoon, JH, et al. Interim analysis of START: Study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial. Int J Cancer 132 (2013), 2448–2458.
24. Erhardt, A, Kolligs, F, Dollinger, M, et al. TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial. Cancer Chemother Pharmacol 74 (2014), 947–954.
25. Kudo, M, Imanaka, K, Chida, N, et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 47 (2011), 2117–2127.
26. Kudo, M, Han, G, Finn, RS, et al. Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial. Hepatology 60 (2014), 1697–1707.
27. Lencioni, R, Llovet, JM, Han, G, et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial. J Hepatol 64 (2016), 1090–1098.
28. Gillmore, R, Stuart, S, Kirkwood, A, et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol 55 (2011), 1309–1316.
29. Kadalayil, L, Benini, R, Pallan, L, et al. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol 24 (2013), 2565–2570.